Fidaxomicin versus vancomycin for Clostridium difficile infection.

By T. Louie, Mark A. Miller, K. Mullane, K. Weiss, A. Lentnek, Y. Golan, S. Gorbach, P. Sears, Y. Shue. New England Journal of Medicine, 2011

1,530 citations recorded by the source corpus.

Subfields: Critical Care and Intensive Care Medicine, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/c55289aab39068390c2b43210a530091b852f564

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. J. H. Morse

Citations in the corpus

• European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. (2014, methodology): “rences in CDI due to PCR ribotype 027 as opposed to non-027 in one of the randomized controlled trials [70].”
• Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. (2011, background): “RCTs have found monoclonal antibodies to be comparable to metronidazole in preventing recurrence (44% and 45%, respectively) [75] and have found intravenous immunoglobulin to reduce the absolute rate of recurrence by 18% in patients who were receiving metronidazole or vancomycin in parallel [76].”